Skip to main content
ProGen, Co,, LTD. logo

ProGen, Co,, LTD. — Investor Relations & Filings

Ticker · 296160 ISIN · KR7296160005 KO Manufacturing
Open in API
Filings indexed 153 across all filing types
Latest filing 2026-05-14 Director's Dealing
Country KR South Korea
Listing KO 296160

About ProGen, Co,, LTD.

https://progen.co.kr

ProGen is an R&D-focused biopharmaceutical company dedicated to developing innovative drugs for incurable diseases, with a primary focus on oncology, immune diseases, and metabolic disorders. The company specializes in creating novel protein-based immunotherapies and antibody therapeutics. Its research and development efforts are driven by proprietary technology platforms, including the NTIG (Neo Tri-ImmunoGlobulin) platform for next-generation multi-specific fusion proteins and the hyFc® platform for long-acting fusion proteins. These technologies enable the engineering of advanced bi-specific and multi-specific therapies designed to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 90% confidence The document is a statutory disclosure by an executive and major shareholder detailing changes in their holdings of the company’s securities, including purchase dates, share counts, and ownership ratios. This matches the insider transaction disclosure category, i.e., reports of personal share transactions by company directors and executives.
2026-05-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 90% confidence The document is a Korean “임원ㆍ주요주주 특정증권등 소유상황보고서,” which details an officer’s specific securities holdings and changes (acquisitions/disposals) on various dates. This is a personal share transaction report by a company director. It matches the definition of Director’s Dealing (insider trading reports).
2026-05-13 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 85% confidence The document is a Korean regulatory disclosure regarding the grant of stock options (주식매수선택권 부여) and an amendment to a prior option‐grant notice. This concerns issuance of potential new shares upon exercise of options, which falls under changes to a company’s share capital rather than a routine earnings or governance report. It is not a director insider trade report (DIRS) nor a buyback (POS), but an announcement of a share issuance/option grant, matching Share Issue/Capital Change (SHA).
2026-05-11 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 65% confidence The document is a Korea Exchange (KRX) disclosure titled “주식매수선택권 부여에 관한 신고” and is a corrected filing (“정정신고”) of the company’s grant of stock options to directors, officers and employees. It details the number of options granted, exercise terms, grant date, and fair value, as well as adjustments due to cancellations. This notice is not a general earnings release, call transcript, or AGM material. It also is not a personal insider trade (DIRS) but rather an issuance of rights to subscribe for new shares. Under the taxonomy, such a corporate action to grant stock options (future share issuance rights) is best mapped to the Share Issue/Capital Change category (SHA).
2026-05-11 Korean
임원ㆍ주요주주특정증권등거래계획철회보고서
Regulatory Filings
2026-05-07 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 92% confidence The document is a detailed ‘주식등의 대량보유상황보고서(약식)’ (Large Shareholding Status Report) filed under Korean capital markets law. It lists the reporter’s and related parties’ shareholdings in (주)에스엘바이젠, changes in holdings by date and method, and contractual arrangements. This aligns exactly with a Major Shareholding Notification rather than an earnings release, management change, or proxy statement. Hence it is classified as MRQ.
2026-04-06 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.